1. Home
  2. OCUL vs MDXG Comparison

OCUL vs MDXG Comparison

Compare OCUL & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OCUL
  • MDXG
  • Stock Information
  • Founded
  • OCUL 2006
  • MDXG 2006
  • Country
  • OCUL United States
  • MDXG United States
  • Employees
  • OCUL N/A
  • MDXG N/A
  • Industry
  • OCUL Biotechnology: Pharmaceutical Preparations
  • MDXG Biotechnology: Pharmaceutical Preparations
  • Sector
  • OCUL Health Care
  • MDXG Health Care
  • Exchange
  • OCUL Nasdaq
  • MDXG Nasdaq
  • Market Cap
  • OCUL 957.3M
  • MDXG 1.0B
  • IPO Year
  • OCUL 2014
  • MDXG N/A
  • Fundamental
  • Price
  • OCUL $7.45
  • MDXG $7.42
  • Analyst Decision
  • OCUL Strong Buy
  • MDXG Strong Buy
  • Analyst Count
  • OCUL 10
  • MDXG 3
  • Target Price
  • OCUL $16.11
  • MDXG $12.00
  • AVG Volume (30 Days)
  • OCUL 1.6M
  • MDXG 809.0K
  • Earning Date
  • OCUL 05-05-2025
  • MDXG 04-30-2025
  • Dividend Yield
  • OCUL N/A
  • MDXG N/A
  • EPS Growth
  • OCUL N/A
  • MDXG N/A
  • EPS
  • OCUL N/A
  • MDXG 0.27
  • Revenue
  • OCUL $59,647,000.00
  • MDXG $352,375,000.00
  • Revenue This Year
  • OCUL $13.32
  • MDXG $9.23
  • Revenue Next Year
  • OCUL $13.13
  • MDXG $11.49
  • P/E Ratio
  • OCUL N/A
  • MDXG $27.33
  • Revenue Growth
  • OCUL N/A
  • MDXG 5.34
  • 52 Week Low
  • OCUL $4.06
  • MDXG $5.47
  • 52 Week High
  • OCUL $11.78
  • MDXG $10.14
  • Technical
  • Relative Strength Index (RSI)
  • OCUL 48.17
  • MDXG 59.64
  • Support Level
  • OCUL $8.07
  • MDXG $6.53
  • Resistance Level
  • OCUL $8.90
  • MDXG $7.07
  • Average True Range (ATR)
  • OCUL 0.48
  • MDXG 0.30
  • MACD
  • OCUL -0.08
  • MDXG 0.09
  • Stochastic Oscillator
  • OCUL 29.68
  • MDXG 99.61

About OCUL Ocular Therapeutix Inc.

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

About MDXG MiMedx Group Inc

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Share on Social Networks: